Found: 20
Select item for more details and to access through your institution.
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 315, doi. 10.1007/s00280-012-1876-0
- By:
- Publication type:
- Article
In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 321, doi. 10.1007/s00280-012-1908-9
- By:
- Publication type:
- Article
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 271, doi. 10.1007/s00280-012-1910-2
- By:
- Publication type:
- Article
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 293, doi. 10.1007/s00280-012-1914-y
- By:
- Publication type:
- Article
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 285, doi. 10.1007/s00280-012-1909-8
- By:
- Publication type:
- Article
Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 277, doi. 10.1007/s00280-012-1912-0
- By:
- Publication type:
- Article
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 305, doi. 10.1007/s00280-012-1916-9
- By:
- Publication type:
- Article
DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 259, doi. 10.1007/s00280-012-1907-x
- By:
- Publication type:
- Article
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 251, doi. 10.1007/s00280-012-1911-1
- By:
- Publication type:
- Article
H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia.
- Published in:
- 2012
- By:
- Publication type:
- Letter
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 221, doi. 10.1007/s00280-012-1904-0
- By:
- Publication type:
- Article
Cetuximab in the first-line treatment of K- ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 231, doi. 10.1007/s00280-012-1898-7
- By:
- Publication type:
- Article
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 213, doi. 10.1007/s00280-012-1899-6
- By:
- Publication type:
- Article
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 239, doi. 10.1007/s00280-012-1906-y
- By:
- Publication type:
- Article
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 345, doi. 10.1007/s00280-012-1881-3
- By:
- Publication type:
- Article
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 2, p. 339, doi. 10.1007/s00280-012-1877-z
- By:
- Publication type:
- Article
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
- Published in:
- 2012
- By:
- Publication type:
- Report